Department of Biotechnology

CEPI will initially contribute up to $5 million toward the cost of scaling up the process for manufacturing the vaccine, and will…

It is an indigenous mRNA vaccine candidate supported with seed grant under the Ind-CEPI mission of Department of Biotechnology of…

She said the vaccines that are being developed indigenously are on different platforms and each has its own benefits and…

The Director of the Institute said that more tests need to be done on mice on a larger scale now and it is expected to start next…

The initiative will work towards fast-tracking development and manufacture of COVID-19 vaccines in the country

It has numerous high-end instrumentation facilities worth Rs 10 crore and is expected to fast track research under biopharma in…

The company’s vaccine candidate has been shortlisted for BIRAC funding, will launch final product by the end of 2022

The vaccine is in its third phase of human trials, Serum Institute of India is partnering Oxford and AstraZeneca to manufacture…

The DBT-BIRAC supported trial aims to evaluate the ability of VPM1002 in reducing infection incidence and severe disease outcomes…

This could help to identify drug targets, formulations for the treatment of COVID-19